Atyr_Logo.png
aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting
March 11, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
logo.jpg
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
March 11, 2021 05:00 ET | ImCheck Therapeutics SAS
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting...
Nurix.png
Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR
March 10, 2021 17:12 ET | Nurix Therapeutics, Inc.
CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cellsPreclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1...
Rubius_Logo.jpg
Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
March 10, 2021 16:30 ET | Rubius Therapeutics
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
September 23, 2020 07:15 ET | MacroGenics, Inc.
Manuscript describes preclinical development of MGC018Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD,...
Neoleukin logo.jpg
Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II
June 22, 2020 09:05 ET | Neoleukin Therapeutics, Inc.
- NL-201 demonstrates durable antitumor activity in animal tumor models -- NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo -- Conditional activation of de novo...
jounce.png
Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting
June 22, 2020 09:00 ET | Jounce Therapeutics, Inc.
- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells - -...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting
June 22, 2020 09:00 ET | MacroGenics, Inc.
Rockville, MD, June 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
amunix logo (high res no tag).png
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
June 22, 2020 09:00 ET | Amunix Pharmaceuticals, Inc.
Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020
June 22, 2020 08:30 ET | Ascendis Pharma
- In vitro data demonstrated selective binding and activation of IL-2 β/γ receptor, associated with reduced IL-2 α receptor binding - - Selective expansion and activation of cells in vivo consistent...